$ITOX
IIOT-OXYS, Inc. Stock $itox

$itox Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000168316824004655 Filed on July 03, 2024

Income Statement

Concept	2024 Q3	2023 Q4	2023
Revenue	$0.00	$16.38K	$114.7K
YoY Change	-100.0%	-66.84%	28.98%
Cost Of Revenue	$0.00	$46.32K	$76.65K
YoY Change	-100.0%	855.05%	630.02%
Gross Profit	$0.00	-$29.94K	$38.02K
YoY Change	-100.0%	-167.21%	-51.51%
Gross Profit Margin		-182.78%	33.16%
Selling, General & Admin		$308.2K	$681.9K
YoY Change		119.95%	-0.24%
% of Gross Profit			1793.54%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$12.48K	$49.50K
YoY Change		0.0%	0.0%
% of Gross Profit			130.19%
Operating Expenses	$155.8K	$320.7K	$731.4K
YoY Change	52.37%	110.13%	-0.23%
Operating Profit	-$155.8K	-$350.6K	-$693.4K
YoY Change	78.24%	224.48%	5.92%
Interest Expense		-$243.2K	$210.4K
YoY Change		40.94%	-44.2%
% of Operating Profit
Other Income/Expense, Net	$51.16K		-$374.5K
YoY Change	21.4%		1.34%
Pretax Income	-$104.7K	-$593.8K	-$1.068M
YoY Change	131.12%	111.61%	4.27%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$104.7K	-$612.6K	-$1.068M
YoY Change	131.12%	103.06%	4.27%
Net Earnings / Revenue		-3739.68%	-931.34%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	555.0M shares	406.8M shares	406.7M shares
Diluted Shares Outstanding	555.0M shares		406.7M shares

Balance Sheet

Concept	2024 Q3	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$640.00	$640.00
YoY Change		-98.08%	-98.08%
Cash & Equivalents	$3.181K	$644.00	$640.00
Short-Term Investments
Other Short-Term Assets		$2.310K	$2.310K
YoY Change		-70.27%	-70.27%
Inventory
Prepaid Expenses
Receivables	$0.00	$5.460K	$5.460K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$5.487K	$8.410K	$8.410K
YoY Change	-88.2%	-87.99%	-87.99%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$161.9K	$199.1K	$199.1K
YoY Change	-60.47%	-55.15%	-55.15%
TOTAL ASSETS
Total Short-Term Assets	$5.487K	$8.410K	$8.410K
Total Long-Term Assets	$161.9K	$199.1K	$199.1K
Total Assets	$167.4K	$207.5K	$207.5K
YoY Change	-63.3%	-59.62%	-59.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$349.4K	$219.6K	$219.6K
YoY Change	266.66%	64.57%	64.57%
Accrued Expenses	$648.6K	$534.1K	$914.7K
YoY Change	26.22%	34.98%	38.76%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$435.0K	$435.0K
YoY Change		19.78%	19.78%
Total Short-Term Liabilities	$2.807M	$2.152M	$2.152M
YoY Change	40.02%	28.31%	28.31%
LONG-TERM LIABILITIES
Long-Term Debt		$58.99K	$58.99K
YoY Change		-43.44%	-43.44%
Other Long-Term Liabilities		$1.000K	$1.000K
YoY Change		0.0%	0.0%
Total Long-Term Liabilities		$59.99K	$59.99K
YoY Change		-43.03%	-43.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.807M	$2.152M	$2.152M
Total Long-Term Liabilities		$59.99K	$59.99K
Total Liabilities	$2.808M	$2.212M	$2.212M
YoY Change	34.95%	24.09%	24.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.22M	-$10.44M
YoY Change	14.1%	12.21%
Common Stock	$555.0K	$470.0K
YoY Change	36.43%	33.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.352M	-$2.623M	-$2.004M
YoY Change
Total Liabilities & Shareholders Equity	$167.4K	$207.5K	$207.5K
YoY Change	-63.3%	-59.62%	-59.62%

Cashflow Statement

Concept	2024 Q3	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$104.7K	-$612.6K	-$1.068M
YoY Change	131.12%	103.06%	4.27%
Depreciation, Depletion And Amortization		$12.48K	$49.50K
YoY Change		0.0%	0.0%
Cash From Operating Activities		-$17.14K	-$146.6K
YoY Change		-90.76%	-77.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities		$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$51.87K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$113.9K
YoY Change		-100.0%	-86.5%
NET CHANGE
Cash From Operating Activities		-17.14K	-$146.6K
Cash From Investing Activities		0.000	$0.00
Cash From Financing Activities		0.000	$113.9K
Net Change In Cash		-17.14K	-$32.69K
YoY Change		1704.21%	142.43%
FREE CASH FLOW
Cash From Operating Activities		-$17.14K	-$146.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001290658
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Security12g Title Security12gTitle	Common Stock, Par Value $0.001
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	801867	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	555015293	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	Fruci & Associates II, PLLC
CY2023	dei	Auditor Firm AuditorFirmId	5525
CY2023	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2022	dei	Auditor Name AuditorName	Haynie & Company
CY2022	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2022	dei	Auditor Firm AuditorFirmId	457
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	644	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33336	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5460	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28941	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2306	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7773	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8410	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	70050	usd
CY2023Q4	ITOX	Originall Issuance Discount On Note Receivable OriginallIssuanceDiscountOnNoteReceivable	0	usd
CY2022Q4	ITOX	Originall Issuance Discount On Note Receivable OriginallIssuanceDiscountOnNoteReceivable	4716	usd
CY2023Q4	ITOX	Note Receivable Net NoteReceivableNet	0	usd
CY2022Q4	ITOX	Note Receivable Net NoteReceivableNet	195284	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	199085	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	248585	usd
CY2023Q4	us-gaap	Assets Assets	207495	usd
CY2022Q4	us-gaap	Assets Assets	513919	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	219551	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	133408	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	534138	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	395714	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	31425	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	31425	usd
CY2023Q4	ITOX	Unearned Interest UnearnedInterest	0	usd
CY2022Q4	ITOX	Unearned Interest UnearnedInterest	5151	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	435000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	363167	usd
CY2023Q4	ITOX	Shares Payable To Related Parties SharesPayableToRelatedParties	15225	usd
CY2022Q4	ITOX	Shares Payable To Related Parties SharesPayableToRelatedParties	14624	usd
CY2023Q4	ITOX	Salaries Payable To Related Parties SalariesPayableToRelatedParties	380579	usd
CY2022Q4	ITOX	Salaries Payable To Related Parties SalariesPayableToRelatedParties	263516	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	535653	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	469873	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2151571	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1676878	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	58988	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	104300	usd
CY2023Q4	ITOX	Due To Stockholders DueToStockholders	1000	usd
CY2022Q4	ITOX	Due To Stockholders DueToStockholders	1000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2211559	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1782178	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	619200	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	544800	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	470015293	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	470015293	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	352174583	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	352174583	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	470016	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	352175	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7350291	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7141877	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10443597	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9307137	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2623264	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1813059	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	207495	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	513919	usd
CY2023	us-gaap	Gross Profit GrossProfit	38021	usd
CY2022	us-gaap	Gross Profit GrossProfit	78405	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49500	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49500	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	214103	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	731420	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	733071	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-4100	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	190462	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-185973	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-200519	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	25969	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	17634	usd
CY2023	us-gaap	Interest Expense InterestExpense	210426	usd
CY2022	us-gaap	Interest Expense InterestExpense	377138	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-374530	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-369561	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1067929	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1024227	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1067929	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1024227	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	68531	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	52654	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1136460	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1076881	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	406685267	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	406685267	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	273238664	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	273238664	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1315853	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1315853	usd
CY2022	ITOX	Common Stock Issued For Financing Commitment CommonStockIssuedForFinancingCommitment	557065	usd
CY2022	ITOX	Sales Commissions Paid On Capital Raise SalesCommissionsPaidOnCapitalRaise	-11141	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	900	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	90000	usd
CY2022	ITOX	Beneficial Conversion Feature Associated With Discounts BeneficialConversionFeatureAssociatedWithDiscounts	-57149	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1076881	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1813059	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1813059	usd
CY2023	ITOX	Common Stock Issued For Financing Commitment CommonStockIssuedForFinancingCommitment	54196	usd
CY2023	ITOX	Sales Commissions Paid On Capital Raise SalesCommissionsPaidOnCapitalRaise	-2324	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4665	usd
CY2023	ITOX	Common Stock Issued For Settlement Of Accrued Interest On Note Payable CommonStockIssuedForSettlementOfAccruedInterestOnNotePayable	18000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	65424	usd
CY2023	ITOX	Loss On Extinguishment Of Notes Payable LossOnExtinguishmentOfNotesPayable	186294	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1136460	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2623264	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2623264	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1136460	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1076881	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4665	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	900	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	214103	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023	ITOX	Discount On Notes Receivable DiscountOnNotesReceivable	0	usd
CY2022	ITOX	Discount On Notes Receivable DiscountOnNotesReceivable	4716	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	12400	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49500	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49500	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-186294	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4663	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17661	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5467	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	86145	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27763	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	248368	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	148558	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	65779	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	267257	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-5151	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	5151	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-15000	usd
CY2023	ITOX	Increase Decrease In Shares Payable To Related Parties IncreaseDecreaseInSharesPayableToRelatedParties	601	usd
CY2022	ITOX	Increase Decrease In Shares Payable To Related Parties IncreaseDecreaseInSharesPayableToRelatedParties	14624	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	117063	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-10410	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-146564	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-657009	usd
CY2023	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	-0	usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	200000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51872	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	545924	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	62000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	297600	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	113872	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	843524	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-32692	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-13485	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33336	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46821	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	644	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33336	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	ITOX	Discount On Notes Payables DiscountOnNotesPayables	0	usd
CY2022	ITOX	Discount On Notes Payables DiscountOnNotesPayables	32852	usd
CY2023	ITOX	Conversion Of Convertible Notes Payable And Derivative Liabilities ConversionOfConvertibleNotesPayableAndDerivativeLiabilities	4665	usd
CY2022	ITOX	Conversion Of Convertible Notes Payable And Derivative Liabilities ConversionOfConvertibleNotesPayableAndDerivativeLiabilities	90000	usd
CY2023	ITOX	Deferred Financing Cost On Notes Payable DeferredFinancingCostOnNotesPayable	75700	usd
CY2022	ITOX	Deferred Financing Cost On Notes Payable DeferredFinancingCostOnNotesPayable	0	usd
CY2023	ITOX	Discount On Series B Convertible Preferred Stock DiscountOnSeriesBConvertiblePreferredStock	0	usd
CY2022	ITOX	Discount On Series B Convertible Preferred Stock DiscountOnSeriesBConvertiblePreferredStock	297600	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zbiDDJSnkJCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously reported net income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zbvc8UrjfYg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued liabilities and payable to related party. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1136460	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10443597	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	644	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33336	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zcLANHa8lrY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_862_zeRDcU4aUIoi">Concentration of Credit Risk</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially expose the Company to concentrations of risk consist primarily of cash and cash equivalents which are generally not collateralized. The Company’s policy is to place its cash and cash equivalents with high quality financial institutions, in order to limit the amount of credit exposure. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC), up to $250,000. At December 31, 2023 and December 31, 2022, the Company had <span id="xdx_90E_eus-gaap--CashUninsuredAmount_iI_pp0p0_do_c20231231_z6othvQ4Lyl3" title="Cash in excess of FDIC insurance limit"><span id="xdx_90E_eus-gaap--CashUninsuredAmount_iI_pp0p0_do_c20221231_zCdb2YNFthK8" title="Cash in excess of FDIC insurance limit">no</span></span> amounts in excess of the FDIC insurance limit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2023Q4	us-gaap	Receivables With Imputed Interest Amortization Amount ReceivablesWithImputedInterestAmortizationAmount	3750	usd
CY2022Q4	us-gaap	Receivables With Imputed Interest Amortization Amount ReceivablesWithImputedInterestAmortizationAmount	2784	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	199085	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	248585	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	495000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	495000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	295915	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	246415	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	199085	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	248585	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	49500	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	49500	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	49500	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	49500	usd
CY2023Q4	ITOX	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	1085	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	493988	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	543167	usd
CY2023Q4	ITOX	Deferred Financing Costs DeferredFinancingCosts	0	usd
CY2022Q4	ITOX	Deferred Financing Costs DeferredFinancingCosts	-75700	usd
CY2023Q4	ITOX	Convertible Notes Payable Net ConvertibleNotesPayableNet	493988	usd
CY2022Q4	ITOX	Convertible Notes Payable Net ConvertibleNotesPayableNet	467467	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	435000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	363167	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	58988	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	104300	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1136460	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1076881	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	406685267	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	406685267	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	273238664	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	273238664	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	840862907	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	369865312	shares
CY2023Q4	ITOX	Due To Stockholders DueToStockholders	1000	usd
CY2022Q4	ITOX	Due To Stockholders DueToStockholders	1000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	11000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	14000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	535653	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	469873	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2868397	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.00084
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y4M24D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2868397	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.00084
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y4M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2868397	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.00084
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y4M24D
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-238657	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-226145	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-55118	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-52229	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	293775	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	278374	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	ITOX	Effective Income Taxes Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxesRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	ITOX	Effective Income Taxes Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxesRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0485	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0485	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0024	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2583	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2561	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2700136	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2405788	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2700136	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2405788	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2700136	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2405788	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	10444000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	9307000	usd

Files In Submission

Name	View Source	Status
0001683168-24-004655-index-headers.html	Edgar Link	pending
0001683168-24-004655-index.html	Edgar Link	pending
0001683168-24-004655.txt	Edgar Link	pending
0001683168-24-004655-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
iiot_ex1058.htm	Edgar Link	pending
iiot_ex3101.htm	Edgar Link	pending
iiot_ex3102.htm	Edgar Link	pending
iiot_ex3201.htm	Edgar Link	pending
iiot_ex3202.htm	Edgar Link	pending
iiot_i10k-123123.htm	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
itox-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
itox-20231231_cal.xml	Edgar Link	unprocessable
itox-20231231_def.xml	Edgar Link	unprocessable
iiot_i10k-123123_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
itox-20231231_lab.xml	Edgar Link	unprocessable
itox-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITOX
IIOT-OXYS, Inc. Stock $itox

2024 Q3 Form 10-K Financial Statement

#000168316824004655 Filed on July 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITOX IIOT-OXYS, Inc. Stock $itox

2024 Q3 Form 10-K Financial Statement

#000168316824004655 Filed on July 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITOX
IIOT-OXYS, Inc. Stock $itox